46 results about "Tissue ischemia" patented technology

The invention discloses a post-arterial paracentesis hemostasis supervision method and related equipment. The method comprises the following steps: monitoring blood flow data of a puncture part of a patient by using a sensor, wherein the blood flow data comprises artery blood flow data and tissue micro blood flow data; based on the pulse blood flow data and the tissue micro blood flow data, the hemostasis effect and the local tissue ischemia condition of the puncture part of the patient are evaluated; and adjusting the hemostasis pressure according to the hemostasis effect and the local tissue ischemia condition. The problems that a traditional manual compression method is time-consuming and labor-consuming, and the hemostatic effect is poor due to misoperation can be solved.

The utility model relates to a self-adaptive pressure tourniquet which comprises a fixing band body, the unfolding face of the fixing band body is in a sector shape with the upper portion wide and the lower portion narrow, rope drawing grooves are formed in the upper end and the lower end of the fixing band body along the edges, corresponding drawing ropes are arranged in the rope drawing grooves, and the other ends of the drawing ropes are movably connected with contraction blocks. The upper end of the side, attached to the skin, of the fixing band body is fixedly connected with a first air bag, the lower end of the side, attached to the skin, of the fixing band body is fixedly connected with a second air bag, and the fan-shaped tourniquet with the wide upper portion and the narrow lower portion can better adapt to differences of limb shapes and sizes of different patients; according to the tourniquet, the fixing band body is arranged, the attaching degree of the fixing band body and the limb is further adjusted through the drawing rope, the tourniquet can be tightly attached to the limb parts with different thicknesses, the multiple air bags can distribute pressure more evenly, and the risk of tissue ischemia and even necrosis caused by uneven pressure is reduced.

According to the pressure damage dynamic risk assessment method based on multi-modal sensing, multi-physical field data is collected in real time through an MEMS piezoresistive array, a near infrared spectrum sensor and a flexible capacitance type humidity sensor, and early precise early warning and automatic grading intervention are achieved in combination with an LSTM neural network and dynamic threshold adjustment. According to the method, the early warning time of the stress injury is advanced by 4-6 hours, so that the clinical misjudgment rate is reduced to be less than 15% from 38%, and the problems that in the prior art, poor blood circulation of subcutaneous tissues cannot be accurately identified by traditional visual inspection, the hysteresis of the currently adopted preventive measures and the clinical accurate judgment error rate are relatively high, and the clinical accuracy is relatively low are solved. In order to solve the problem that the occurrence risk and the compression degree of the stress injury cannot be accurately judged due to the fact that the existing tissue ischemia assessment method is based on the three-layer architecture of'multi-modal sensing and dynamic modeling combined with intelligent closed loop ', the transformation from'passive discovery' to'active prevention 'is realized, and a more comprehensive tissue ischemia assessment system is constructed.

The invention provides a non-classical ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound with a good inhibition effect on ferroptosis, the compound can be used for preparing a ferroptosis inhibitor, and the structure of the compound is shown as a formula I in the specification. The compound can be used for preparing medicines for preventing and / or treating ferroptosis-related neurodegenerative diseases, tissue ischemia-reperfusion injury, cerebral apoplexy, cardiovascular diseases, renal failure, inflammation, cardiotoxicity, acute organ injury, chronic atrophic gastritis or diabetic complications and other diseases, and has a wide market prospect. # imgabs0 #

The utility model discloses a balloon dilatation catheter with a double-cannula structure, relates to the technical field of medical instruments, and solves the technical problem that far-end myocardium or tissue ischemia of a patient is easily caused when a balloon of the balloon dilatation catheter is kept in a dilatation state for a long time. Comprising an outer tube, an inner tube penetrating through the outer tube and a balloon arranged on the outer tube in a sleeving mode, the outer tube is composed of a first outer tube body and a second outer tube body, the inner tube is composed of a first inner tube body and a second inner tube body, a transition part of an annular structure is installed between the first outer tube body and the second outer tube body, and a blood channel is formed in the transition part in the axial direction in a penetrating mode. The blood channel is communicated between the first inner tube and the second inner tube, and a guide wire is arranged in the blood channel, the first inner tube and the second inner tube in a penetrating mode. When the balloon is kept in an expansion state for a long time, blood of a patient can still penetrate through the balloon to supply blood to far-end myocardium or tissue, so that body injury caused by lack of normal blood supply to the patient is avoided.

The hemostasis compressor comprises an equipment support, the front end of the equipment support is provided with a compression mechanism used for compressing a wound, the compression mechanism comprises a movable bin, the interior of the movable bin is movably connected with a pressing plate, and the bottom of the pressing plate is fixedly connected with a first magnet; two movable rods are movably connected to the interior of the pressing plate, the two movable rods are fixedly connected through a first spring, and buckles are further movably connected to the side faces of the movable rods; by means of the device, locking can be quickly unlocked to adjust the compression force, hemostasis requirements of different patients are met, complications such as bleeding, hematoma or tissue ischemia caused by improper pressure are reduced, seamless connection of tube drawing and hemostasis is achieved, operation steps are reduced, meanwhile, delay of manual adjustment of a compressor after tube drawing in a traditional process is avoided, and the hemostasis efficiency is improved. The formation risk of subcutaneous ecchymosis and hematoma is reduced, and the hemostasis efficiency and safety are improved.

The utility model relates to an intraoperative intermittent inflatable anti-pressure eyeshade, the intraoperative intermittent inflatable anti-pressure eyeshade comprises an eyeshade main body, a first pipeline and a second pipeline, the first pipeline is arranged in the eyeshade main body, a plurality of support air bags are arranged on the first pipeline, the second pipeline is arranged in the eyeshade main body, the support air bags are arranged on the second pipeline, and the support air bags are arranged on the support air bags. A plurality of first supporting air bags are arranged on the first pipeline, a plurality of second supporting air bags are arranged on the second pipeline, and the first supporting air bags on the first pipeline and the second supporting air bags on the second pipeline are alternately arranged, fully distributed on the periphery of the eyeshade body and correspond to the peripheral positions of eye sockets. The first supporting air bag of the first pipeline and the second supporting air bag of the second pipeline can intermittently protrude out of the eyeshade main body during inflation so as to support skin tissues around eye sockets, so that pressure is prevented from being applied to the same part for a long time, and the risk of ischemia and hypoxia of the tissues around the eye sockets is reduced; the formation of pressure sores is prevented.

The invention discloses a 10H-phenoxazine compound as well as a preparation method and application thereof. The 10H-phenoxazine compound has a structure as shown in a formula (I). The invention also discloses application of the compounds and pharmaceutically acceptable salts thereof, or crystal forms thereof, or solvates thereof, or stereoisomers thereof in preparation of ferroptosis inhibitors, and application of the compounds and pharmaceutically acceptable salts thereof in preparation of drugs for treating and / or preventing neurodegenerative diseases, tissue ischemia reperfusion injury, cerebral apoplexy, cardiovascular diseases, renal failure, liver injury, diabetic complications, diabetes mellitus and the like. The invention relates to application in medicines for treating pancreatic cancer. # imgabs0 #

The present invention discloses a hemostatic compressor for interventional cardiology surgery, comprising an equipment bracket, a compression mechanism for compressing a wound provided at the front end of the equipment bracket, the compression mechanism comprising a movable bin, a pressing plate movably connected inside the movable bin, and a magnet 1 fixedly connected to the bottom of the pressing plate, two movable rods movably connected inside the pressing plate, and the two movable rods are fixedly connected by a spring 1, and a buckle is also movably connected on the side of the movable rod; the above-mentioned device can be quickly unlocked to adjust the compression force to meet the hemostasis needs of different patients, reduce complications such as bleeding, hematoma or tissue ischemia caused by improper pressure, and achieve seamless connection between extubation and hemostasis, reduce the number of operating steps, avoid the delay of manually adjusting the compressor after extubation in the traditional process, reduce the risk of subcutaneous ecchymosis and hematoma formation, and improve hemostasis efficiency and safety.

The utility model relates to the technical field of medical instruments, in particular to a catheter. The catheter comprises a catheter body, and a plurality of side holes and valves are arranged on the periphery of the far end of the catheter body. At least two valves are respectively arranged at each side hole of the catheter body; the pressure in the catheter body is larger than the pressure outside the catheter body, and the adjacent valves can abut against each other to seal the corresponding side holes. The pressure in the catheter body is smaller than the pressure outside the catheter body, and channels can be formed between the valves to open the side holes. According to the technical scheme, the problems that in the prior art, forward blood flow at the near end of the aorta is blocked due to the fact that the size of a duct tube is large, tissue ischemia of the blocked portion is caused, and operation risks are increased are solved.

The present invention discloses an application of a PAI-1 inhibitor in the preparation of a drug for treating liver ischemia-reperfusion injury, and relates to the field of biomedicine technology. The present invention selects PAI-1 gene knockout mice and C57BL / 6 wild-type mice as experimental subjects, constructs mouse liver ischemia-reperfusion injury models respectively, and studies the function of PAI-1 in liver ischemia-reperfusion injury. The study found that after PAI-1 knockout, it can reduce liver ischemia-reperfusion injury by affecting the formation and recruitment of liver neutrophil induction network, inhibiting the inflammatory response of the liver. PAI-1 is a key gene that affects neutrophil activation and is an important target for regulating inflammatory response during the reperfusion period. Animal experiments have verified that the PAI-1 specific inhibitor PAI-039 can reduce the degree of injury of mouse liver ischemia-reperfusion, providing new ideas for the development of new drugs for preventing, alleviating and / or treating tissue ischemia-reperfusion injury.

This invention relates to the field of medical device technology and discloses a multifunctional auxiliary device for thyroid surgery, comprising: a base; a tension band; a binding block; a base component connected to the binding block, the base component including a fixed ring and a movable ring, the fixed ring being connected to the binding block, the movable ring being rotatably mounted on top of the fixed ring, and the movable ring being coaxial with the fixed ring; traction components, with several sets of traction components mounted on the movable ring; and a drive mechanism. By setting a rotatable movable ring and multiple sets of traction components, during surgery, the drive mechanism drives the movable ring to rotate intermittently in both directions, causing several rotating rods to intermittently change positions at the incision site, thereby continuously changing the stress points of the incision tissue. This allows tissues in different areas to take turns bearing the traction force and receiving blood perfusion, effectively avoiding local tissue ischemia, hypoxia, and plastic deformation caused by stress concentration in traditional traction devices, significantly protecting tissue activity, and promoting postoperative healing.

A method for preventing or treating a cerebrovascular disease or a tissue ischemia-reperfusion injury is provided. The method comprises administering to a patient a drug containing a pharmaceutically effective amount of LY2922470. The embodiments of the present disclosure confirm the significant potential of LY2922470 as a drug for cerebrovascular diseases and tissue ischemia-reperfusion injury. For the first time, it is disclosed that LY2922470 effectively improves infarct lesions, providing an effective new potential alternative drug for the treatment of related cerebrovascular diseases and tissue ischemia-reperfusion injury, expanding the indications of LY2922470, and greatly enhancing the application potential and market prospects of LY2922470.

The invention relates to hUCMSCs for efficient ischemic injury repair and a preparation method and application thereof, and relates to the technical field of biology, the preparation method comprises the following steps: obtaining P2-generation hUCMSCs cells; under the conditions that the oxygen concentration volume fraction range is 1%-10% and an inflammatory factor pre-activation composition is added, subculture multiplication culture is conducted on the P2-generation hUCMSCs cells, and the hUCMSCs for efficient ischemic injury repair are obtained, wherein the inflammatory factor pre-activation composition is prepared from the following components: 10 to 50 ng / ml of TNF (Tumor Necrosis Factor)-a, 10 to 50 ng / ml of IL-1beta and the like. According to the invention, the problems of low content of paracrine cytokines for promoting angiogenesis and inhibiting inflammatory response, poor in-vivo microenvironment adaptability and the like of the existing hUCMSCs are solved, the hUCMSCs can play a better role in repairing tissue ischemic injury, and the defects of the prior art are overcome.

The utility model provides a compression hemostasis device for postoperative care for liver cancer intervention, which relates to the technical field of medical instruments and comprises a connecting block, a compression component is fixedly connected to one side of the connecting block, a cooling component is slidably connected to one side, close to the compression component, of the connecting block, and a connecting component is fixedly connected to the bottom end of the cooling component. The compression assembly comprises an outer-layer nylon belt, one end of the outer-layer nylon belt is fixedly connected to the connecting block, through the design, accurate control over compression force is achieved, the hemostasis effect is guaranteed, discomfort or secondary damage to a patient is avoided, pressure is evenly distributed through an inner-layer nylon bag, the compression force is more uniform, and the compression effect is better. And by using the cooling belt, vasodilatation caused by heat accumulation is effectively prevented, the hemostasis effect is improved, the risk of tissue ischemia or injury is avoided, and the problem that a traditional compression hemostasis device is difficult to ensure that the pressure applied to a wound is uniform and consistent is effectively solved.

The present invention provides a preparation method and application of umbilical cord mesenchymal stem cells, belonging to the field of biomedical technology. By using the conditioned medium of umbilical cord blood venous endothelial cells secreting exosomes for 48 hours as the basic component, compounding the serum "containing compound Chinese medicine ingredients" as the culture system of umbilical cord mesenchymal stem cells, and compounding hypoxia culture, the obtained mesenchymal stem cells are used to treat post-stroke cognitive impairment (PSCI). The umbilical cord mesenchymal stem cells of the present invention can penetrate the brain-blood barrier and improve the ischemia and hypoxia of tissues in the cerebral infarction area, and also provide a new way of synergistic treatment of PSCI biological treatment and traditional Chinese medicine treatment.

The present invention relates to an intravascular occlusion device for occluding a lumen of an intravascular system to treat certain medical conditions, such as vascular malformation, vascular hemorrhage or occluding a blood vessel to cause tissue ischemia or necrosis, the occlusion device comprising: a deformable cannula, the deformable sleeve is displaceable between a contracted state and an expanded state; and a tapered array of cantilevers extending from a distal end of the cannula and converging toward a distal tip defining a first hemostasis valve around the distal end of the cannula. The distal end of the cannula will be at least partially covered by a polymer fluid impermeable film to provide a seal to prevent fluid flow through the occlusion device. The internal valve will be hemostatic regardless of the initial direction of blood flow and will allow distal intravascular delivery of a surgical instrument, such as a catheter, that can be manipulated and used to deliver a therapeutic agent, such as a liquid or small particle embolism.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

The invention discloses application of palmitoleic acid in preparation of a medicine for protecting nerves and treating cerebral ischemia-reperfusion injury, and belongs to the field of biological medicine. Animal experiments prove the neuroprotective effect of palmitoleic acid on cerebral ischemia-reperfusion injury for the first time. By establishing a mouse cerebral ischemia reperfusion injury model, the palmitoleic acid is found to be capable of remarkably improving neurological impairment and reducing the volume and area of cerebral infarction, which indicates that the palmitoleic acid can be used for effectively limiting ischemic necrosis of brain tissues. According to the application, the research limitation that palmitoleic acid is traditionally applied to metabolic diseases is broken through, a brand new treatment strategy is provided for solving clinical ischemic stroke reperfusion injury, a solid foundation is laid for developing novel neuroprotective drugs, and important clinical application value and development prospects are shown in the aspect of improving prognosis of stroke patients.

The invention relates to the technical field of hemostasis equipment, in particular to portable air pressure self-adaptive pressing hemostasis equipment which comprises a disc, an air bag is mounted at the bottom of the disc, a piezoelectric sensor is mounted at the bottom of the air bag, and the top of the air bag is communicated with an air delivery pipe; the device can be conveniently and rapidly operated in environments such as hospital emergency rooms and wards or under outdoor emergency conditions, the hemostasis response time is greatly shortened, the device is carried and used in various scenes, the target pressure value is automatically or manually adjusted on the control panel according to bleeding condition changes of parts such as groins, wrists and elbows, and the hemostasis efficiency is improved. The device responds in real time and adjusts the pressure of the air bag, the hemostasis requirements of different stages are met, the stable and efficient hemostasis effect is maintained in the complicated and changeable treatment environment of a hospital, the situations that tissue ischemia hypoxia necrosis is caused by too large pressure or subcutaneous hematoma and hemostasis cannot be achieved due to too small pressure are avoided, and the hemostasis accuracy and safety are improved.

A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.

A fixation device for the treatment of diabetic peripheral neuropathy, belonging to the field of fixation technology, aims to address the problem that prolonged pressure on the same location during long-term treatment can easily lead to pressure marks, ischemic injuries, or even pressure sores. The invention includes a bed frame with two placement plates fixedly installed on one side. A lifting seat is fixedly installed on the surface of each placement plate. Three moving parts are evenly distributed below the lifting seats. A driving component is fixedly installed on one side of the lifting seats. Three adjusting seats are slidably connected to the surfaces of the three moving parts. A first rolling pressure plate is fixedly installed at one end of the adjusting seat in the middle position, and a second rolling pressure plate is rotatably connected to one end of the adjusting seats on either side. This invention allows for switching between different pressure points, avoiding prolonged pressure on the same location and preventing the risk of local tissue ischemia and necrosis. Furthermore, it maintains the fixation of the lower leg while switching between different pressure points, improving the stability of the lower leg during treatment.

The utility model relates to a balloon catheter which comprises a catheter body, a balloon and a limiting layer, the balloon is arranged on the periphery of the catheter body in a sleeved mode and can expand or contract, and a through flow channel is formed between the balloon and the catheter body in the expanded state. The limiting layer comprises an outer limiting layer covering the outer side of the balloon, and the compliance of the outer limiting layer is smaller than that of the balloon. When the balloon is expanded, a through flow channel is formed between the balloon and the catheter, so that blood passes through the flow channel while the balloon is tightly attached to the wall of a blood vessel, ischemia or necrosis of far-end tissue is avoided, the balloon can be placed in the blood vessel for a longer time, and a better expansion effect is achieved; the limiting layer can limit the diameter of the balloon within a set range, the dog bone effect can be effectively prevented, and the treatment effect is good.

This invention relates to the field of intelligent hemostasis and discloses an intelligent tourniquet control method and system based on data analysis. The method includes continuously acquiring data on tourniquet tension displacement, contact surface pressure feedback, and limb pulse response, and performing dynamic synchronous correction according to the correspondence between pressure inflection points and pulsation attenuation nodes in each sensor signal. By comparing the offset relationship between the circumferential pressure change rate and distal micropulsation residue, a hidden pressure relief segment in the effective occlusion state is identified. After the contact instability map is expanded along the circumferential contact boundary of the tourniquet, environmental fluctuations and blood flow recovery characteristics are separated. When the dynamic force transmission distribution enters a continuous change phase, high-frequency fluctuation segments within the compression safety window are processed. The pressure replenishment rhythm and release interval of the drive component are adjusted with reference to the stable boundary migration trajectory. The hemostasis control result is output based on the hemostasis completion rate, tissue ischemia risk, and environmental interference level. This invention has the advantage of improving hemostasis stability in complex environments.

The present application relates to a kind of device for treating anal fistula, comprising: silk thread;Magnetic beads, spherical structure, the number of the magnetic beads is multiple, multiple the magnetic beads are connected on the silk thread;Blocking structure, fixedly connected in the middle of the silk thread, for blocking the inner mouth of the anal fistula.The device for treating anal fistula provided by the present application can be used instead of probe, and will not damage the tissue around fistula;Through the magnetism of magnetic beads, the magnetic beads in the inner mouth of anal fistula can be easily sucked out of the anus, without finger into anus blind find, easy to operate;After the device passes through fistula, the magnetic beads at both ends of silk thread are attracted to form closed loop structure, and the magnetic attraction between the magnetic beads generates continuous compression force on the tissue in closed loop, so that the tissue in closed loop is ischemic necrosis, and the reliability during use is improved, since silk thread is not easy to break;Blocking structure can reliably block the inner mouth of anal fistula, prevent dirt from entering fistula, and is beneficial to healing.

The invention discloses a tension adjusting system and method of an incision retractor, and relates to the technical field of medical instruments, the tension adjusting system comprises a flexible channel, a built-in ring is arranged at the far end of the flexible channel, and a fixed base is arranged at the near end of the flexible channel; the central tension adjusting system comprises a plurality of first adjusting belts, the first adjusting belts are embedded in the wall of the flexible channel and evenly distributed in the circumferential direction of the flexible channel, and the far ends of the first adjusting belts are fixedly connected with the far-end built-in ring. According to the invention, through dual mechanisms of manual central adjustment and automatic cooperative adjustment and in combination with a unique non-equilibrium compensation mode, precise, stable and adaptive control of the retraction force of the surgical incision is realized, so that the uniformity and stability of exposure of the surgical field are remarkably improved; and tissue ischemia injury caused by overlarge local pressure can be effectively avoided, and meanwhile, the operation convenience of a doctor and the safety of an operation process are enhanced.

The application belongs to the technical field of medical equipment, and particularly relates to a pressing hemostasis device for a cardiology department, which comprises a mounting box, wherein the mounting box is in a ring shape, a PLC controller is fixedly connected to the upper side wall of the mounting box, a micro power supply is connected to the inner wall of the mounting box, an internally-threaded cylinder is inserted into the mounting box, the internally-threaded cylinder is rotationally connected to the inner wall of the mounting box through a bearing, and a self-locking threaded rod is inserted into the internally-threaded cylinder in a threaded manner. Before the pressing hemostasis device is placed on a puncture point on the arm of a patient for pressing hemostasis, different pressures can be applied to the puncture point according to the thickness of the arm of the patient, so that the blood vessels are ensured to be closed under sufficient compression, and the blood vessels are also prevented from bearing excessive pressure, so that tissue ischemia, hypoxia, pain, numbness and other uncomfortable symptoms are caused.

The invention discloses a protective restraint strap, and relates to the field of protective restraint, the protective restraint strap comprises two sleeve straps, one side of each sleeve strap is provided with a fastening mechanism, each fastening mechanism comprises a flexible shell, and one side of each flexible shell is fixedly connected with one side of the adjacent sleeve strap; according to the protective restraint strap, the medical grade silica gel and breathable fiber mixed material is adopted, the self-adaptive air bag, the pressure sensor and the infrared multifunctional sensor are combined to form a closed-loop monitoring system, the pressure and blood flow state can be sensed in real time, the servo motor is automatically triggered to adjust the tightness degree when the pressure and blood flow state is abnormal, and tissue ischemia is avoided; one-key automatic tightening and accurate control are achieved through a servo motor, a tooth column and a clamping rack in the fastening mechanism, and the operation efficiency and the standardization level are improved; and the retaining ring mechanism is connected with an external anchor point by virtue of a rope belt, and is matched with a magnetic attraction and insertion structure of a magnet block and a clamping groove, so that the anti-struggling capability is enhanced, and comfortable, intelligent and safe multi-dimensional constraint is integrally realized.

This invention relates to the field of medical device technology and provides a balloon, comprising: a balloon body; and a traction wire adapted to the balloon body. The traction wire applies stress to at least a portion of the surface of the balloon body in its inflated state, causing at least one indentation to form on the surface of the balloon body connecting its proximal and distal sides. When the balloon body remains inflated, the indentation forms a channel allowing partial blood flow. The balloon provided by this invention can intermittently block or open bypass channels during surgery, avoiding complete blockage of blood flow during balloon expansion. This achieves the effect of occlusion without complete shut-off, reducing significant blood loss and preventing ischemia and necrosis of downstream tissues.

This invention provides a medical compression stocking, comprising: a stocking body and raised granules. One end of the stocking body has an open toe opening. The stocking body is worn from the patient's foot to below the knee, and includes an ankle pressure zone and a foot pressure zone. The ankle pressure zone provides a pressure range of 15–21 mmHg, and the ratio of the pressure provided by the foot pressure zone to that provided by the ankle pressure zone is 0.3–0.4. Multiple raised granules are spaced apart on the inner side of the stocking body. The highest point is below the knee and completely covers the foot, with only the toes exposed, making it easy to put on and take off, facilitating direct observation of nail bed blood circulation, and avoiding pressure relaxation caused by repeated removal of the stocking. The gradient pressure avoids excessive pressure on the toes, eliminating the risk of tissue ischemia. The raised granules provide continuous static pressure stimulation, which helps shorten the recovery time of postoperative bowel sounds and reduce abdominal distension. No active manipulation is required, making it particularly suitable for bedridden patients, thereby improving recovery outcomes.